| __timestamp | MiMedx Group, Inc. | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 90480000 | 40786000 |
| Thursday, January 1, 2015 | 133384000 | 47876000 |
| Friday, January 1, 2016 | 179997000 | 52035000 |
| Sunday, January 1, 2017 | 220119000 | 55348000 |
| Monday, January 1, 2018 | 258528000 | 65276000 |
| Tuesday, January 1, 2019 | 198205000 | 82720000 |
| Wednesday, January 1, 2020 | 181022000 | 89118000 |
| Friday, January 1, 2021 | 198359000 | 181193000 |
| Saturday, January 1, 2022 | 208789000 | 174078000 |
| Sunday, January 1, 2023 | 211124000 | 184232000 |
Unlocking the unknown
In the competitive landscape of healthcare companies, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. From 2014 to 2023, MiMedx Group, Inc. consistently reported higher SG&A expenses compared to Veracyte, Inc. However, the trend reveals a fascinating shift. MiMedx's SG&A expenses grew by approximately 133% over the decade, while Veracyte's expenses surged by an impressive 352%. Despite MiMedx's higher absolute costs, Veracyte's rapid increase suggests aggressive expansion strategies. By 2023, Veracyte's SG&A expenses reached nearly 88% of MiMedx's, up from just 45% in 2014. This data highlights Veracyte's dynamic growth and strategic investments in administrative capabilities. Investors and stakeholders should consider these trends when evaluating the operational efficiency and future potential of these companies.
Selling, General, and Administrative Costs: Novo Nordisk A/S vs MiMedx Group, Inc.
Selling, General, and Administrative Costs: AbbVie Inc. vs Veracyte, Inc.
Merck & Co., Inc. and Veracyte, Inc.: SG&A Spending Patterns Compared
Incyte Corporation and MiMedx Group, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Walgreens Boots Alliance, Inc. and Veracyte, Inc.
Jazz Pharmaceuticals plc vs MiMedx Group, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.
Comparing SG&A Expenses: Alkermes plc vs MiMedx Group, Inc. Trends and Insights
Comparing SG&A Expenses: Verona Pharma plc vs MiMedx Group, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and HUTCHMED (China) Limited
Operational Costs Compared: SG&A Analysis of Veracyte, Inc. and Travere Therapeutics, Inc.
Veracyte, Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?